A Diagnostics & Imaging Week

Atherotech (Birmingham, Alabama), a developer of cardio-diagnostic technology, including its VAP cholesterol test, reported a series of restructuring initiatives that it said will strengthen its management infrastructure and position it for its next phase of growth.

Roseanne Varner has stepped down as president/ CEO and will be replaced by David Schreiber, who has joined Atherotech as acting president/CEO. Schreiber is a long-time consultant to the company.

The company also named Dr. Kneeland Youngblood chairman of the board. Youngblood is co-founder and managing partner of Pharos Capital (Dallas), a long-time Atherotech shareholder. Youngblood currently serves on Atherotech’s board.

The company also reported forming an executive management committee to provide guidance for its next stage of growth. The committee includes: Dr. Lawrence Greer, senior managing director of Greer Capital Advisors (Birmingham); and Atherotech executives Michael Mullen, CFO, and Robert Shufflebarger, VP of operations.

Youngblood praised Varner’s contribution since co-founding the company in 1999. “We appreciate Roseanne’s vision and her efforts to grow the company. Now, it’s time to augment the management infrastructure with new executive skill sets that will position Atherotech to leap beyond the 3.5 million VAP tests performed since the company’s inception and beat the 2006 record of one million tests in just one year.”